O	0	1	A	A	DT	B-NP
O	2	7	novel	novel	JJ	I-NP
O	8	16	integrin	integrin	NN	I-NP
O	17	28	alpha5beta1	alpha5beta1	NN	I-NP
O	29	41	antagonistic	antagonistic	JJ	I-NP
O	42	49	peptide	peptide	NN	I-NP
O	49	50	,	,	,	O
O	51	53	A5	A5	NN	B-NP
O	53	54	-	-	HYPH	B-NP
O	54	55	1	1	CD	I-NP
O	55	56	,	,	,	O
O	57	65	screened	screen	VBN	B-VP
O	66	68	by	by	IN	B-PP
O	69	76	Protein	Protein	NN	B-NP
O	77	81	Chip	Chip	NN	I-NP
O	82	88	system	system	NN	I-NP
O	89	91	as	as	IN	B-PP
O	92	93	a	a	DT	B-NP
O	94	100	potent	potent	JJ	I-NP
O	101	113	angiogenesis	angiogenesis	NN	I-NP
O	114	123	inhibitor	inhibitor	NN	I-NP
O	123	124	.	.	.	O

O	125	133	Integrin	Integrin	NN	B-NP
O	134	145	alpha5beta1	alpha5beta1	NN	I-NP
O	146	157	immobilized	immobilize	VBN	B-VP
O	158	160	on	on	IN	B-PP
O	161	162	a	a	DT	B-NP
O	163	173	ProteoChip	ProteoChip	NN	I-NP
O	174	177	was	be	VBD	B-VP
O	178	182	used	use	VBN	I-VP
O	183	185	to	to	TO	B-VP
O	186	192	screen	screen	VB	I-VP
O	193	196	new	new	JJ	B-NP
O	197	209	antagonistic	antagonistic	JJ	I-NP
O	210	218	peptides	peptide	NNS	I-NP
O	219	223	from	from	IN	B-PP
O	224	232	multiple	multiple	JJ	B-NP
O	233	244	hexapeptide	hexapeptide	NN	I-NP
O	245	248	sub	sub	AFX	B-NP
O	248	249	-	-	HYPH	I-NP
O	249	258	libraries	library	NNS	B-NP
O	259	261	of	of	IN	B-PP
O	262	265	the	the	DT	B-NP
O	266	276	positional	positional	JJ	I-NP
O	277	285	scanning	scanning	NN	I-NP
O	286	295	synthetic	synthetic	JJ	I-NP
O	296	303	peptide	peptide	NN	I-NP
O	304	317	combinatorial	combinatorial	JJ	I-NP
O	318	325	library	library	NN	I-NP
O	326	327	(	(	(	O
O	327	329	PS	PS	NN	B-NP
O	329	330	-	-	HYPH	B-NP
O	330	334	SPCL	SPCL	NN	I-NP
O	334	335	)	)	)	O
O	335	336	.	.	.	O

O	337	340	The	The	DT	B-NP
O	341	349	integrin	integrin	NN	I-NP
O	350	361	alpha5beta1	alpha5beta1	NN	I-NP
O	361	362	-	-	HYPH	B-NP
O	362	373	Fibronectin	Fibronectin	NN	I-NP
O	374	385	interaction	interaction	NN	I-NP
O	386	389	was	be	VBD	B-VP
O	390	402	demonstrated	demonstrate	VBN	I-VP
O	403	405	on	on	IN	B-PP
O	406	409	the	the	DT	B-NP
O	410	414	chip	chip	NN	I-NP
O	414	415	.	.	.	O

O	416	417	A	A	DT	B-NP
O	418	423	novel	novel	JJ	I-NP
O	424	431	peptide	peptide	NN	I-NP
O	432	438	ligand	ligand	NN	I-NP
O	438	439	,	,	,	O
O	440	442	A5	A5	NN	B-NP
O	442	443	-	-	HYPH	B-NP
O	443	444	1	1	CD	I-NP
O	445	446	(	(	(	O
O	446	452	VILVLF	VILVLF	NN	B-NP
O	452	453	)	)	)	O
O	453	454	,	,	,	O
O	455	459	with	with	IN	B-PP
O	460	464	high	high	JJ	B-NP
O	465	473	affinity	affinity	NN	I-NP
O	474	476	to	to	TO	B-PP
O	477	485	integrin	integrin	NN	B-NP
O	486	497	alpha5beta1	alpha5beta1	NN	I-NP
O	498	501	was	be	VBD	B-VP
O	502	512	identified	identify	VBN	I-VP
O	513	517	from	from	IN	B-PP
O	518	521	the	the	DT	B-NP
O	522	533	hexapeptide	hexapeptide	NN	I-NP
O	534	543	libraries	library	NNS	I-NP
O	544	548	with	with	IN	B-PP
O	549	553	this	this	DT	B-NP
O	554	558	chip	chip	NN	I-NP
O	558	559	-	-	HYPH	B-VP
O	559	564	based	base	VBN	B-NP
O	565	574	screening	screening	NN	I-NP
O	575	581	method	method	NN	I-NP
O	582	584	on	on	IN	B-PP
O	585	588	the	the	DT	B-NP
O	589	594	basis	basis	NN	I-NP
O	595	597	of	of	IN	B-PP
O	598	599	a	a	DT	B-NP
O	600	611	competitive	competitive	JJ	I-NP
O	612	622	inhibition	inhibition	NN	I-NP
O	623	628	assay	assay	NN	I-NP
O	628	629	.	.	.	O

O	630	632	A5	A5	NN	B-NP
O	632	633	-	-	HYPH	B-NP
O	633	634	1	1	CD	I-NP
O	635	643	inhibits	inhibit	VBZ	B-VP
O	644	647	the	the	DT	B-NP
O	648	656	integrin	integrin	NN	I-NP
O	656	657	-	-	HYPH	B-NP
O	657	668	fibronectin	fibronectin	NN	I-NP
O	669	680	interaction	interaction	NN	I-NP
O	681	683	in	in	IN	B-PP
O	684	685	a	a	DT	B-NP
O	686	690	dose	dose	NN	I-NP
O	690	691	-	-	HYPH	B-NP
O	691	700	dependent	dependent	JJ	I-NP
O	701	707	manner	manner	NN	I-NP
O	708	709	(	(	(	O
O	709	711	IC	IC	NN	B-NP
O	711	712	(	(	(	O
O	712	714	50	50	CD	B-NP
O	714	715	)	)	)	O
O	715	716	;	;	:	O
O	717	718	1	1	CD	B-NP
O	718	719	.	.	.	I-NP
O	719	721	56	56	CD	I-NP
O	721	722	+	+	SYM	O
O	722	723	/	/	SYM	O
O	723	724	-	-	SYM	B-NP
O	724	725	0	0	CD	B-NP
O	725	726	.	.	SYM	I-NP
O	726	728	28	28	CD	I-NP
O	729	735	microM	microM	NN	I-NP
O	735	736	.	.	.	O

O	737	739	In	In	IN	B-PP
O	740	748	addition	addition	NN	B-NP
O	748	749	,	,	,	O
O	750	752	it	it	PRP	B-NP
O	753	761	inhibits	inhibit	VBZ	B-VP
B-Cell	762	767	human	human	JJ	B-NP
I-Cell	768	777	umbilical	umbilical	JJ	I-NP
I-Cell	778	782	vein	vein	NN	I-NP
I-Cell	783	794	endothelial	endothelial	JJ	I-NP
I-Cell	795	799	cell	cell	NN	I-NP
O	800	813	proliferation	proliferation	NN	I-NP
O	813	814	,	,	,	O
O	815	824	migration	migration	NN	B-NP
O	824	825	,	,	,	O
O	826	834	adhesion	adhesion	NN	B-NP
O	834	835	,	,	,	O
B-Multi-tissue_structure	836	843	tubular	tubular	JJ	B-NP
I-Multi-tissue_structure	844	851	network	network	NN	I-NP
O	852	861	formation	formation	NN	I-NP
O	861	862	,	,	,	O
O	863	866	and	and	CC	O
O	867	871	bFGF	bFGF	NN	B-NP
O	871	872	-	-	HYPH	O
O	872	879	induced	induce	VBN	B-NP
O	880	898	neovascularization	neovascularization	NN	I-NP
O	899	901	in	in	IN	B-PP
O	902	903	a	a	DT	B-NP
O	904	909	chick	chick	NN	I-NP
B-Multi-tissue_structure	910	925	chorioallantoic	chorioallantoic	JJ	I-NP
I-Multi-tissue_structure	926	934	membrane	membrane	NN	I-NP
O	934	935	.	.	.	O

O	936	941	These	These	DT	B-NP
O	942	949	results	result	NNS	I-NP
O	950	957	suggest	suggest	VBP	B-VP
O	958	962	that	that	IN	B-SBAR
O	963	965	A5	A5	NN	B-NP
O	965	966	-	-	HYPH	B-NP
O	966	967	1	1	CD	I-NP
O	968	972	will	will	MD	B-VP
O	973	975	be	be	VB	I-VP
O	976	977	a	a	DT	B-NP
O	978	984	potent	potent	JJ	I-NP
O	985	994	inhibitor	inhibitor	NN	I-NP
O	995	997	of	of	IN	B-PP
O	998	1016	neovascularization	neovascularization	NN	B-NP
O	1016	1017	.	.	.	O

